Contineum Files Corporate Overview Presentation
Contineum Therapeutics filed an 8-K containing a corporate overview presentation highlighting risks related to its clinical pipeline candidates. The document emphasizes dependence on the success of early-stage drug trials and potential regulatory uncertainties.
View filing at SEC.gov →